Please assess the completion status of the following clinical trial:

Trial Title: Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject was male, 16 years of age or older (18 years of age or older in the US), and post pubertal,(minimum age by region)~2. Subject had a confirmed diagnosis of classic Fabry disease based on deficient AGA enzyme activity (defined as \< 1% of normal).~Exclusion Criteria:~1. Subject had a galactosidase alpha (GLA) gene mutation associated with late-onset cardiac variant Fabry disease.~2. Subject had previously received ERT and/or chaperone therapy within 3 years for treatment of Fabry disease.~3. Subject had tested positive for anti-AGA antibodies at the time of screening.~4. Subject had eGFR \< 60 mL/min/1.73 m² (ie, chronic kidney disease \[CKD\] stage ≥ 3) at Screening.~5. Subject had a prior history of myocardial infarction (MI).~6. Subject had a history of coronary artery disease (CAD) with angina requiring percutaneous transluminal coronary angioplasty (with or without stent placement) and/or coronary artery bypass graft (CABG).~7. Subject had a history of moderate to severe valvular heart disease requiring valve replacement.~8. Subject had a history of heart failure, moderate to severe diastolic dysfunction, and/or left ventricular ejection fraction (LVEF) ≤ 45% on echocardiogram (ECHO) performed at rest at Screening.~9. Subject had a history of clinically significant cardiac arrhythmia (eg, heart block \[second or third degree\], atrial fibrillation requiring therapy, ventricular fibrillation, ventricular tachycardia, supraventricular tachycardia, or cardiac arrest).~   Note \[history of intermittent atrial fibrillation not requiring treatment was allowed\].~10. Subject had a prior history of stroke and/or transient ischemic attack (TIA).~11. Subject had aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN) at Screening.~12. Subject had a prior history of (or current) malignancy; the one exception is a prior history of resected basal cell carcinoma.~13. Subject had previously received treatment with AVR-RD-01 or any other gene therapy.~Other inclusion/exclusion criteria apply.

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Single Assignment AVR-RD-01 (Type: EXPERIMENTAL): AVR-RD-01 is an autologous CD34+-enriched cell fraction transduced with LV/AGA containing an RNA transcript that, after reverse transcription, results in codon-optimized cDNA that, upon its integration into the human genome, encodes for functional human AGA.

Based on this trial design, predict the completion outcome and termination type (if applicable).